

Publikationen

Prof. Dr. habil. Carsten Boltze (Stand Januar 2018)

A) Originalarbeiten (peer-reviewed und in PubMed gelistet)

Hinze R, Boltze C, Meye A, Holzhausen HJ, Dralle H, Rath FW (2000) Expression of the von Hippel-Lindau tumor suppressor gene in nonneoplastic and neoplastic lesions of the thyroid. *Endocr Pathol*, 11:145-155 IF: 1.724

Boltze C, Schneider-Stock R, Jäger V, Roessner A (2001) Distinction between lipoma and liposarcoma by mdm2 alterations: a case report of simultaneously occurring tumors and review of the literature. *Pathol Res Pract*, 197:563-568 IF: 0.850

Aust G, Steinert M, Boltze C, Kiessling S, Simchen C (2001) GRO- in normal and pathological thyroid tissues and its regulation in thyroid-derived cells. *J Endocrinol*, 170:513-520 IF: 3.319

Hribaschek A, Kuhn R, Pross M, Lippert H, Halangk W, Boltze C, Ridwelski K (2001) Prophylaxis of peritoneal carcinomatosis in experimental investigations. *Int J Colorectal Dis*, 16:340-345 IF: 1.902

Boltze C, Brabant G, Dralle H, Gerlach R, Roessner A, Hoang-Vu C (2002) Radiation-induced thyroid carcinogenesis as function of time and dietary iodine supply - An in-vivo model of tumorigenesis in the rat. *Endocrinology*, 143:2584-2592 IF: 5.313

Mawrin C, Lins H, Koenig B, Heinrichs T, Murayama S, Kirches E, Boltze C, Dietzmann K (2002) Spatial and temporal disease progression of adult-onset subacute sclerosing panencephalitis. *Neurology*, 58:1568-1571 IF: 5.973

Boltze C, Schneider-Stock R, Aust G, Mawrin C, Dralle H, Roessner A, Hoang-Vu C (2002) CD97, CD95 and Fas-L clearly discriminate between chronic pancreatitis and pancreatic ductal adenocarcinoma in perioperative evaluation of cryocut sections. *Pathol Int*, 52:83-88 IF: 1.073

Mawrin C, Kirches E, Boltze C, Dietzmann K, Roessner A, Schneider-Stock R (2002) Immunohistochemical and molecular analysis of p53, Rb and PTEN in malignant peripheral nerve sheath tumors. *Virchows Arch*, 440:610-615 IF: 2.227

Ondruschka C, Buhtz P, Motsch C, Freigang B, Schneider-Stock, Roessner A, Boltze C (2002) Prognostic value of MMP-2, -9 and TIMP-1, -2 immunoreactive protein at the invasive front in advanced head and neck squamous cell carcinomas. *Pathol Res Pract*, 198:509-515 IF: 1.073

Steinert M, Wobus M, Boltze C, Schütz A, Wahlbuhl M, Hamann J, Aust G (2002) Expression and regulation of CD97 on colorectal cell lines and carcinomas. *Am J Pathol*, 161:1657-1667 IF: 6.750

Schneider-Stock R, Boltze C, Roessner A (2002) Telomerase and new aspects for tumor. *Pathologie*, 23:177-182 IF: 0.592

Mawrin C, Kirches E, Boltze C, Dietzmann K (2002) PTEN is not altered in sporadic vestibular schwannomas. *Histopathology*, 40:526-531 IF: 4.131

Boltze C, Roessner A, Landt O, Szibor R, Peters B, Schneider-Stock R (2002) Homozygous proline at codon 72 of p53 as a potential risk factor favoring the development of undifferentiated thyroid carcinoma. *Int J Oncol*, 21:1151-1154 IF: 3.056

Hoang-Vu C, Boltze C, Gimm O, Poremba C, Dockhorn-Dworniczak B, Köhrle J, Rath FW, Dralle H (2002) Expression of telomerase genes in thyroid carcinoma. *Int J Oncol*, 21:265-272 IF: 3.056

Aust G, Steinert M, Schütz A, Boltze C, Wahlbuhl M, Hamman J, Wobus M (2002) CD97, but not its closely related EGF-TM7 family member EMR2 is expressed on gastric, pancreatic and esophageal carcinomas. *Am J Clin Pathol*, 118:699-707 IF: 2.853

Schneider-Stock R, Boltze C, Jäger V, Stumm M, Seiler C, Rys J, Schütze K, Roessner A (2002) Significance of loss of heterozygosity of the RB1 gene during tumour progression in well-differentiated liposarcomas. *J Pathol*, 197:654-660 IF: 5.333

Hribaschek A, Pross M, Kuhn R, Krüger S, Ridwelski K, Halangk W, Boltze C, Lippert H (2002) Prevention and treatment of peritoneal carcinomatosis in experimental investigations with CPT-11 and oxaliplatin. *Anti-Cancer Drugs*, 13:605-614 IF: 2.052

Mawrin C, Kirches E, Dietzmann K, Roessner A, Boltze C (2002) Expression pattern of apoptotic markers in vestibular schwannomas. *Pathol Res Pract*, 198:813-820 IF: 1.073

Hribaschek A, Ridwelski K, Pross M, Meyer F, Kuhn R, Halangk W, Boltze C, Lippert H (2003) Intraperitoneal treatment using Taxol is effective for experimental peritoneal carcinomatosis in a rat model. *Oncol Rep* 10:1793-1798 IF: 1.525

Schneider-Stock R, Gerresheim F, Kolin-Gerresheim I, Meyer F, Jäger V, Epplen JT, Roessner A, Boltze C (2003) Different mRNA expression profile during tumor progression in a well-differentiated liposarcoma – a microdissection approach. *Pathol Res Pract*, 199:445-450 IF: 1.073

Schneider-Stock R, Giers A, Motsch C, Boltze C, Evert M, Freigang B, Roessner A (2003) Hereditary p16-Leiden mutation in a patient with multiple head and neck cancer. *Am J Hum Genet*, 72:216-218 IF: 12.340

Boltze C, Hribaschek A, Lippert H, Roessner A (2003) Intermuscular chondrolipoma of the thigh: the diagnostic way of a rare entity. *Pathol Res Pract*, 199:503-507 IF: 1.073

Mawrin C, Dietsch S, Treuheit T, Kropf S, Vorwerk CK, Boltze C, Kirches E, Firsching R, Dietzmann K (2003) Prognostic relevance of MAPK expression in glioblastoma multiforme. *Int J Oncol*, 23:641-648 IF: 3.056

Röpke M, Boltze C, Neumann HW, Roessner A, Schneider-Stock R (2003) Genetic and epigenetic alterations in tumor progression of a dedifferentiated chondrosarcoma. *Pathol Res Pract*, 199:437-444 IF: 1.073

Schneider-Stock R, Boltze C, Jäger V, Epplen J, Landt O, Peters B, Rys J, Roessner A (2003) Elevated telomerase activity, c-Myc, and hTERT mRNA expression – markers for tumor progression in malignant lipomatous tumors. *J Pathol*, 199:517-525 IF: 5.333

Boltze C, Zack S, Quednow C, Bettke S, Roessner A, Schneider-Stock R (2003) Hypermethylation of the CDKN2 / p16INK4A promoter in thyroid carcinogenesis. *Pathol Res Pract*, 199:399-404 IF: 1.073

Boltze C, Schneider-Stock R, Meyer F, Peters B, Quednow C, Hoang-Vu C, Roessner A (2003) Maspin in thyroid cancer: its relationship with p53 and clinical outcome. *Oncol Rep*, 10:1783-1788 IF: 1.525

Mawrin C, Grimm C, von Falkenhausen U, Kirches E, Scherlach C, Kanakis D, Vorwerk C, Boltze C, Firsching R, Dietzmann K (2003) Pineal epidermoid coinciding with pineocytoma. *Acta Neurochir*, 145:783-78 IF: 1.080

Boltze C, Schneider-Stock R, Quednow C, Hinze R, Mawrin C, Hribaschek A, Roessner A, Hoang-Vu C (2003) Silencing of the Maspin gene by promoter hypermethylation in thyroid cancer. *Int J Mol Med*, 11:479-484 IF: 3.190

Schneider-Stock R, Boltze C, Lasota J, Miettinen M, Peters B, Pross M, Roessner A, Günther T (2003) High prognostic value of p16INK4 alterations in gastrointestinal stromal tumors. *J Clin Oncol*, 21:1688-1697 IF: 10.864

Schneider-Stock R, Boltze C, Peters B, Höpfner T, Meyer F, Lippert H, Roessner A (2003) Differences in loss of p16INK4A protein expression by promoter methylation between left- and right-sided primary colorectal carcinomas. *Int J Oncol*, 23:1009-1013 IF: 3.056

Naka T, Boltze C, Samii A, Herold C, Ostertag H, Iwamoto Y, Oda Y, Tsuneyoshi M, Kuester D, Roessner A (2003) Skull base and non-skull-base chordomas. Clinicopathologic and immunohistochemical study with special reference to nuclear pleomorphism and proliferative ability. *Cancer*, 98:1934-1941 IF: 4.434

Boltze C, Schneider-Stock R, Roessner A, Quednow C, Hoang-Vu C (2003) Function of HSP90 and p23 in the telomerase complex of thyroid tumors. *Pathol Res Pract*, 199:573-579 IF: 1.073

Semczuk A, Boltze C, Marzec B, Szczygielska A, Roessner A, Schneider-Stock R (2003) p16 INK4A alterations are accompanied by aberrant protein immunostaining in endometrial carcinomas. *J Cancer Res Clin Oncol*, 129:589-596 IF: 2.409

Lasota J, Dansonka-Mieszkowska A, Stachura T, Schneider-Stock R, Kallajoki M, Steigen SE, Sarlomo-Rikala M, Boltze C, Kordek R, Roessner A, Stachura J, Miettinen M (2003) Gastrointestinal stromal tumors with internal tandem duplications in 3' end of KIT juxtamembrane domain occur predominantly in stomach and generally seem to have a favorable course. *Mod Pathol*, 16:1257-1264 IF: 3.643

Boltze C, Mundschenk J, Unger N, Schneider-Stock R, Peters B, Mawrin C, Hoang-Vu C, Roessner A, Lehnert H (2003) Expression profile of the telomeric complex discriminates between benign and malignant pheochromocytoma. *J Clin Endocrinol Metab*, 88:4280-4286 IF: 6.020

Lasota J, Kopczynski J, Sarlomo-Rikala M, Schneider-Stock R, Stachura T, Kordek R, Michal M, Boltze C, Roessner A, Stachura J, Miettinen M (2003) KIT 1530ins6 mutation defines a subset of predominantly malignant gastrointestinal stromal tumors of intestinal origin. *Hum Pathol*, 34:1306-1312 IF: 3.685

Boltze C, Schneider-Stock R, Quednow C, Gerlach R, Mawrin C, Hinze R, Roessner A, Hoang-Vu C (2003) Proteome analysis identified Maspin as a special feature of papillary thyroid carcinoma. *Int J Oncol*, 23:1323-1328 IF: 3.056

Koon N, Schneider-Stock R, Sarlomo-Rikala M, Lasota J, Smolkin M, Petroni G, Zaika A, Boltze C, Meyer F, Andersson L, Knuutila S, Miettinen M, El-Rifai W (2004) Molecular targets for tumor progression in gastrointestinal stromal tumors (GISTs). *Gut*, 53:235-240 IF: 6.601

Dworakowska D, Jassem E, Jassem J, Wiedorn KH, Boltze C, Karmolinski A, Dworakowski R, Skokowski J, Jaskiewicz K, Bosse A, Czestochowska E (2004) Prognostic Relevance of Altered pRb and p53 Protein Expression in Surgically Treated Non-Small Cell Lung Cancer Patients. *Oncology*, 67:60-66 IF: 2.114

Schneider-Stock R, Boltze C, Peters B, Szibor R, Landt O, Meyer F, Roessner A (2004) Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer. *Neoplasia*, 6:529-535 IF: 4.377

Motsch C, Giers A, Boltze C, Evert M, Freigang B, Roessner A, Schneider-Stock R (2004) Biallelic inactivation of the p16 gene in three metachronous carcinoma of the oropharynx. *Laryngo Rhino Otol*, 83:55-60 IF: 0.507

Boltze C (2004) Animal models of thyroid carcinogenesis. *Cancer Treat Res*, 122:273-293 IF: 3.515

Gali-Muhtasib H, Diab-Assaf M, Boltze C, Al-Hmaira J, Hartig R, Roessner A, Schneider-Stock R (2004) Thymoquinone extracted from black seed triggers apoptotic cell death in human colorectal cancer cells via a p53-dependent mechanism. *Int J Oncol*, 25:857-866 IF: 3.056

Naka T, Boltze C, Kuester D, Schulz TO, Samii A, Herold C, Ostertag H, Roessner A (2004) Expression of Matrix Metalloproteinase (MMP)-1, MMP-2, MMP-9, cathepsin B, and urokinase plasminogen activator in non-skull base chordoma. *Am J Clin Pathol*, 122:926-930 IF: 2.853

Schneider-Stock R, Mawrin C, Motsch C, Boltze C, Peters B, Hartig R, Buhtz P, Giers A, Rohrbeck A, Freigang B, Roessner A (2004) Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer. *Am J Pathol*, 164:1233-1241 IF: 6.750

Schneider-Stock R, Boltze C, Lasota J, Peters B, Corless CL, Ruemmele P, Terracciano L, Pross M, Insabato L, Di Vizio D, Iesalnieks I, Dirnhofer S, Hartmann A, Heinrich M, Miettinen M, Roessner A, Tornillo L (2005) Loss of p16 protein defines high-risk patients with Gastrointestinal Stromal Tumors- A tissue microarray study. *Clin Cancer Res*, 11: 638-645 IF: 6.511

Naka T, Boltze C, Kuester D, Samii A, Herold C, Ostertag H, Iwamoto Y, Oda Y, Tsuneyoshi M, Roessner A (2005) Histogenesis of intralesional fibrous septum in chordoma. *Pathol Res Pract*, 201:443-447 IF: 1.073

Mawrin A, Kirches E, Schneider-Stock R, Boltze C, Vorwerk CK, Deimling A, Stoltenburg-Didinge G, Bornemann A, Romeike B, Sellhaus B, Dietzmann K (2005) Alterations of cell cycle regulators in gliomatosis cerebri. *J Neurooncol*, 72:115-122 IF: 1.968

Dworakowska D, Jassem E, Jassem J, Boltze C, Wiedorn KH, Dworakowski R, Skokowski J, Jaskiewicz K, Czestochowska E (2005) Absence of prognostic significance of p21(WAF1/CIP1) protein expression in non-small cell lung cancer. *Acta Oncol*, 44: 75-79 IF: 2.084

Schneider-Stock R, Diab-Asseff M, Rohrbeck A, Foltzer-Jourdainne C, Boltze C, Hartig R, Schönfeld P, Roessner A, Gali-Muhtasib H (2005) 5-AZA-cytidine is a potent inhibitor of DNA methyltransferase 3a and induces apoptosis in HCT-116 colon cancer cells via Gadd45- and p53-dependent mechanisms. *J Pharmacol Exp Ther*, 312:525-536 IF: 4.335

Dworakowska D, Jassem E, Jassem J, Boltze C, Wiedorn KH, Dworakowski R, Skokowski J, Jaskiewicz K, Czestochowska E (2005) Prognostic value of cyclin D1 overexpression in correlation with pRb and p53 status in non-small cell lung cancer (NSCLC). *J Cancer Res Clin Oncol*, 131:479-485 IF: 2.409

Naka T, Boltze C, Kuester D, Schulz TO, Schneider-Stock R, Kellner A, Samii A, Herold C, Ostertag H, Roessner A (2005) Alterations of G1-S checkpoint in chordoma: Prognostic impact of p53 overexpression. *Cancer*, 104:1255-1263 IF: 4.434

Boltze C (2005) Loss of maspin is a helpful prognosticator in colorectal cancer: A tissue microarray analysis. *Pathol Res Pract*, 200:783-790 IF: 1.073

Naka T, Boltze C, Kuester D, Samii A, Herold C, Ostertag H, Iwamoto Y, Oda Y, Tsuneyoshi M, Roessner A (2005) Intralesional fibrous septum in chordoma: A clinicopathologic and immunohisto-chemical study of 122 lesions. *Am J Clin Pathol*, 124:288-294 IF: 2.853

Hribaschek A, Kuhn R, Pross M, Meyer F, Fahlke J, Ridwelski K, Boltze C, Lippert H (2006) Comparison of intraperitoneal versus intravenous CPT-11 given intra- and postoperatively for peritoneal carcinomatosis in a rat model. *Surg Today*, 36:57-62 IF: 0.553

Röpke M, Boltze C, Meyer B, Neumann HW, Roessner A, Schneider-Stock R (2006) Rb-loss is associated with high malignancy in chondrosarcoma. *Oncol Rep*, 15:89-95 IF: 1.525

Schneider-Stock R, Kuester D, Ullrich O, Mittag F, Habold C, Boltze C, Peters B, Krueger S, Hintze C, Meyer F, Hartig R, Roessner A (2006) Close localization of DAP-kinase positive tumor-associated macrophages and apoptotic colorectal cancer cells. *J Pathol*, 209:95-105 IF: 5.333

Aust G, Wandel E, Boltze C, Sittig, D, Steinert M, Schütz A, Horn LC, Wobus M (2006) Diversity of CD97 in smooth muscle cells (SMCs). *Cell Tissue Res*, 324:139-147 IF: 2.750

Just T, Stave J, Boltze C, Wree A, Kramp B, Guthoff RF, Pau HW (2006) Laser scanning microscopy of the human larynx mucosa: a preliminary, ex vivo study. *Laryngoscope*, 116:1136-1141 IF: 1.576

Port M, Boltze C, Wang Y, Röper B, Meineke V, Abend M (2007) A radiation-induced gene signature distinguishes post-Chernobyl from sporadic papillary thyroid cancers. *Radiat Res*, 168:639-649 IF: 3.043

Zehlicke T, Punke C, Haase K, Boltze C, Pau HW (2008) Myxoma of the middle ear-a rare cause of facial palsy. *HNO*, 56:165-168 IF: 0.653

Naka T, Kuester D, Boltze C, Scheil-Bertram S, Samii A, Herold C, Ostertag H, Krueger S, Roessner A (2008) Expression of hepatocyte growth factor and c-MET in skull base chordoma. *Cancer*, 112:104-110 IF: 4.434

Punke C, Zehlicke T, Boltze C, Pau HW (2008) Experimental studies on a new highly porous hydroxyapatite matrix for obliterating open mastoid cavities. *Otol Neurotol*, 29:807-811 IF: 1.219

Förster G, Boltze C, Seidel J, Pawlita M, Müller A (2008) Juvenile laryngeal papillomatosis - immunisation with the polyvalent vaccine gardasil. *Laryngo Rhino Otol*, 87:796-799 IF: 0.507

Zehlicke T, Punke C, Boltze C, Pau HW (2008) Transient facial palsy in two cases of benign, very rare middle ear tumors (carcinoid tumor and myxoma). *Neurologist*, 14:52-55 IF: 1.662

Naka T, Kuester D, Boltze C, Schulz TO, Samii A, Herold C, Ostertag H, Roessner A (2008) Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma. *Hum Pathol*, 39:217-223 IF: 3.685

Punke C, Zehlicke T, Boltze C, Pau HW (2009) Investigation of a new highly porous hydroxyapatite matrix for obliterating open mastoid cavities - application in guinea pigs bulla. *Laryngo Rhino Otol*, 88:241-246 IF: 0.507

Naka T, Boltze C, Samii A, Samii M, Herold C, Ostertag H, Iwamoto Y, Oda Y, Tsuneyoshi M, Kuester D, Roessner A (2009) Expression of c-MET, low-molecular-weight cytokeratin, matrix metalloproteinases-1 and -2 in spinal chordoma. *Histopathology*, 54:607-613 IF: 4.131

Boltze C, Riecke A, Ruf CG, Port M, Nizze H, Kügler C, Miethke C, Wiest N, Abend M (2009) Sporadic and radiation-associated papillary thyroid cancers can be distinguished using routine immunohistochemistry. *Oncol Rep*, 22:459-467 IF: 1.525

Schmuecking M, Boltze C, Geyer H, Salz H, Schilling B, Wendt TG, Kloetzer KH, Marx C (2009) Dynamic MRI and CAD vs. choline MRS: where is the detection level for a lesion characterisation in prostate cancer? *Int J Radiat Biol*, 85:814-824 IF: 2.690

Lesser TG, Ritter F, Schlosser H, Boltze C, Hackenbroich C (2011) Effects of radiofrequency ablation on normal lung tissue in a swine model. *Acad Radiol*, 18:1318-1323 IF: 2.195

Rödel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, Graeven U, Arnold D, Lang-Welzenbach M, Raab HR, Sülberg H, Wittekind C, Potapov S, Staib L, Hess C, Weigang-Köhler K, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R, Boltze C et al. for German Rectal Cancer Study Group (2012) Preoperative chemoradiotherapy and

postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. *Lancet Oncol*, 13:679-687 IF: 24.725

Lesser K, Boltze C, Böttcher J, Lesser TG (2012) Cystic medionecrosis of the carotid bifurcation as an uncommon cause of stroke. *Neurologist*, 18:395-397 IF: 1.662

Lesser TG, Wolfram F, Boltze C (2013) Sealing of pulmonary arteries with LigaSure: In vivo and ex vivo examinations. *J Thorac Cardiovasc Surg*, 145:1525-1528 IF: 3.406

Moskalev EA, Stöhr R, Rieker R, Hebele S, Fuchs F, Sirbu H, Mastitsky SE, Boltze C, König H, Agaimy A, Hartmann A, Haller F (2013) Increased detection rates of EGFR and KRAS mutations in NSCLC specimens with low tumour cell content by 454 deep sequencing. *Virchows Arch*, 462:409-419 IF: 2.227

Wolfram F, Boltze C, Schubert H, Bischoff S, Lesser TG (2014) Effect of lung flooding and high-intensity focused ultrasound on lung tumours: an experimental study in an ex vivo human cancer model and simulated in vivo tumours in pigs. *Eur J Med Res*, 19:1-9 IF: 1.400

Barthelmeß S, Geddert H, Boltze C, Moskalev EA, Bieg M, Sirbu H, Brors B, Wiemann S, Hartmann A, Agaimy A, Haller F (2014) Solitary fibrous tumors/hemangiopericytomas with different variants of the NAB2-STAT6 gene fusion are characterized by specific histomorphology and distinct clinicopathological features. *Am J Pathol*, 184:1209-1218 IF: 6.750

Moskalev EA, Frohnauer J, Merkelbach-Bruse S, Schildhaus H, Dimmler A, Schubert T, Boltze C, König H, Fuchs F, Sirbu H, Rieker RJ, Agaimy A, Hartmann A, Haller F (2014) Sensitive and specific detection of EML4-ALK rearrangements in non-small cell lung cancer (NSCLC) specimens by multiplex amplicon RNA massive parallel sequencing. *Lung Cancer*, 84:215-221 IF: 3.373

Agaimy A, Barthelmeß S, Geddert H, Boltze C, Moskalev EA, Koch M, Wiemann S, Hartmann A, Haller F (2014) Phenotypical and molecular distinctness of sinonasal haemangiopericytoma compared to solitary fibrous tumour of the sinonasal tract. *Histopathology*, 65:667-673 IF: 4.131

Haller F, Bieg M, Moskalev EA, Barthelmeß S, Geddert H, Boltze C, Diessl N, Braumandl K, Brors B, Iro H, Hartmann A, Wiemann S, Agaimy A (2015) Recurrent Mutations within the Amino-Terminal Region of β -Catenin are probable Key Molecular Driver Events in Sinonasal Hemangiopericytoma. *Am J Pathol*, 185:563-571 IF: 6.750

Rödel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, Hofheinz RD, Ghadimi M, Wolff HA, Lang-Welzenbach M, Raab HR, Wittekind C, Ströbel P, Staib L, Wilhelm M, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R, Liersch T; Boltze C et al. for German Rectal Cancer Study Group (2015) Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol*, 16:979-989 IF: 24.725

Foerster G, Arnold D, Bischoff S, Boltze C, Scholle HC, Schubert H, Mueller AH (2016) Pre-clinical evaluation of a minimally invasive laryngeal pacemaker system in mini-pig. *Eur Arch Otorhinolaryngol*, 273:151-158 IF: 1.545

Hunstig F, Schulz S, Nieten I, Froster U, Boltze C, Schliemann S, Hochhaus A, La Rosée P (2016) A case of Brooke-Spiegler syndrome with a novel mutation in the CYLD gene in a patient with aggressive non-Hodgkin's lymphoma. *J Cancer Res Clin Oncol*, 142:845-848 IF: 3.081

Lesser TG, Boltze C, Schubert H, Wolfram F (2016) Flooded Lung Generates a Suitable Acoustic Pathway for Transthoracic Application of High Intensity Focused Ultrasound in Liver. *Int J Med Sci*, 13:741-748 IF: 2.399

Weyerer V, Schneckenpointner R, Filbeck T, Burger M, Hofstaedter F, Wild PJ, Fine SW, Humphrey PA, Dehner LP, Amin MB, Rüschoff J, Boltze C, Tannapfel A, Zwarthoff E, Lopez-Beltran A, Montironi R, Langner C, Stoehr R, Hartmann A, Giedl J (2017) Immunohistochemical and molecular characterizations in urothelial carcinoma of bladder in patients less than 45 years. *J Cancer*, 8:323-331 IF: 2.916

Wolfram F, Dietrich G, Boltze C, Jenderka KV, Lesser TG (2017) Effects of HIFU induced cavitation on flooded lung parenchyma. *J Ther Ultrasound*, 5:21-28 IF: 1.455

B) Übersichtsartikel

Roessner A, Schneider-Stock R, Boltze C (2001) Pathology of soft tissue tumors. *Viszeralchir*, 36: 203-208

Boltze C, Heutling D, Lehnert H (2002) Molecular pathogenesis of endocrine tumors. *Internist*, 43:157-173

Schneider-Stock R, Giers A, Boltze C, Evert M, Freigang B, Roessner A, Motsch C (2003) Molekulargenetik als wichtige Säule der Tumordiagnostik: Identifizierung erblicher Karzinompatienten. *Tumorz akt*, 1:4-8

Boltze C, Hoang-Vu C, Schneider-Stock R, Lehnert H, Roessner A (2004) Role of the class II tumor suppressor gene maspin in thyroid carcinogenesis. *Verh Dtsch Ges Pathol*, 88:237-245

C) weitere Publikationen

Buchbeiträge

Hoang-Vu C, Boltze C, Sekulla C, Dralle H, Gerlach R, Dunst J, Holzhausen HJ, Brabant G. Functional and histomorphological changes of thyrocytes under different iodine intake and external ionizing radiation in rats. In: Thomas G, Karaoglou A, Williams ED (Eds.): *Radiation and thyroid cancer*. World Scientific, Singapur, New Jersey, London, Hongkong, 1999, pp 209-212

Schneider-Stock R, Boltze C, Roessner A. Telomerase activity in mesenchymal tumors. In: Krupp G, Pawaresch R (Eds.): *Telomeres and Telomerases: Cancer and Biology*. LandesBioscience / Eurekah.com, Georgetown, TX, 2002, pp 41-46

Boltze C. Animal models of thyroid carcinogenesis. In: Farid NR (Ed.): *Molecular basis of thyroid cancer*. Kluwer Academic Publishers, Norwell, MA, 2004, pp 272-293